on GENFIT (EPA:GNFT)
GENFIT makes available the 2025 Universal Registration Document
The biopharmaceutical company GENFIT has announced the filing of its 2025 Universal Registration Document with the French Financial Markets Authority (AMF). This document includes various reports such as the annual financial report and the reports of the statutory auditors. It is available on GENFIT's website as well as on the AMF's website.
GENFIT, based in Lille, Paris, Zurich, and Cambridge, aims to improve treatments for rare liver diseases. It continues to develop its therapeutic assets, notably with the approval of elafibranor for Primary Biliary Cholangitis in 2024.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news